Literature DB >> 24933328

Dexmedetomidine decreases inhibitory but not excitatory neurotransmission to cardiac vagal neurons in the nucleus ambiguus.

Douglas B Sharp1, Xin Wang2, David Mendelowitz3.   

Abstract

Dexmedetomidine, an α2 adrenergic agonist, is a useful sedative but can also cause significant bradycardia. This decrease in heart rate may be due to decreased central sympathetic output as well as increased parasympathetic output from brainstem cardiac vagal neurons. In this study, using whole cell voltage clamp methodology, the actions of dexmedetomidine on excitatory glutamatergic and inhibitory GABAergic and glycinergic neurotransmission to parasympathetic cardiac vagal neurons in the rat nucleus ambiguus was determined. The results indicate that dexmedetomidine decreases both GABAergic and glycinergic inhibitory input to cardiac vagal neurons, with no significant effect on excitatory input. These results provide a mechanism for dexmedetomidine induced bradycardia and has implications for the management of this potentially harmful side effect.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac vagal neuron; Dexmedetomidine; Inhibitory; Neurotransmission

Mesh:

Substances:

Year:  2014        PMID: 24933328      PMCID: PMC4128000          DOI: 10.1016/j.brainres.2014.06.010

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  Dexmedetomidine: another arrow for the clinician's quiver.

Authors:  Thomas Ebert; Mervyn Maze
Journal:  Anesthesiology       Date:  2004-09       Impact factor: 7.892

2.  Dexmedetomidine and cardiac arrest.

Authors:  Esperanza Ingersoll-Weng; Gerard R Manecke; Patricia A Thistlethwaite
Journal:  Anesthesiology       Date:  2004-03       Impact factor: 7.892

3.  Optogenetic stimulation of locus ceruleus neurons augments inhibitory transmission to parasympathetic cardiac vagal neurons via activation of brainstem α1 and β1 receptors.

Authors:  Xin Wang; Ramón A Piñol; Peter Byrne; David Mendelowitz
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

4.  Dexmedetomidine.

Authors:  N Bhana; K L Goa; K J McClellan
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

5.  Bradycardia leading to asystole during dexmedetomidine infusion in an 18 year-old double-lung transplant recipient.

Authors:  Xiaopeng Zhang; Ulrich Schmidt; John C Wain; Luca Bigatello
Journal:  J Clin Anesth       Date:  2010-02       Impact factor: 9.452

6.  Dexmedetomidine does not attenuate increases in excitatory amino acids after transient global ischemia in the rabbit.

Authors:  H K Kim; M H Zornow; M A Strnat; M Maze
Journal:  J Neurosurg Anesthesiol       Date:  1996-07       Impact factor: 3.956

7.  Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial.

Authors:  Richard R Riker; Yahya Shehabi; Paula M Bokesch; Daniel Ceraso; Wayne Wisemandle; Firas Koura; Patrick Whitten; Benjamin D Margolis; Daniel W Byrne; E Wesley Ely; Marcelo G Rocha
Journal:  JAMA       Date:  2009-02-02       Impact factor: 56.272

8.  Effects of dexmedetomidine on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices.

Authors:  P Talke; P E Bickler
Journal:  Anesthesiology       Date:  1996-09       Impact factor: 7.892

9.  The effects of dexmedetomidine on cardiac electrophysiology in children.

Authors:  Gregory B Hammer; David R Drover; Hong Cao; Ethan Jackson; Glyn D Williams; Chandra Ramamoorthy; George F Van Hare; Alisa Niksch; Anne M Dubin
Journal:  Anesth Analg       Date:  2008-01       Impact factor: 5.108

10.  A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients.

Authors:  Anthony T Gerlach; Joseph F Dasta; Steven Steinberg; Larry C Martin; Charles H Cook
Journal:  J Crit Care       Date:  2009-08-13       Impact factor: 3.425

View more
  5 in total

Review 1.  Parasympathetic Vagal Control of Cardiac Function.

Authors:  Jhansi Dyavanapalli; Olga Dergacheva; Xin Wang; David Mendelowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 2.  Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrine       Date:  2015-12-12       Impact factor: 3.633

3.  Dexmedetomidine Attenuates Bilirubin-Induced Lung Alveolar Epithelial Cell Death In Vitro and In Vivo.

Authors:  Jian Cui; Hailin Zhao; Bin Yi; Jing Zeng; Kaizhi Lu; Daqing Ma
Journal:  Crit Care Med       Date:  2015-09       Impact factor: 7.598

4.  Adrenergic agonist induces rhythmic firing in quiescent cardiac preganglionic neurons in nucleus ambiguous via activation of intrinsic membrane excitability.

Authors:  Isamu Aiba; Jeffrey L Noebels
Journal:  J Neurophysiol       Date:  2019-01-30       Impact factor: 2.714

5.  Effects of intranasal and intramuscular dexmedetomidine in cats receiving total intravenous propofol anesthesia.

Authors:  Kewvaree Hommuang; Panpicha Sattasathuchana; Naris Thengchaisri
Journal:  Vet World       Date:  2022-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.